

USCOMM-DC 80-398.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P0554C2

Serial No.

08/355,460

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Hudziak, R. et al.

Filing Date

13 Dec 1994

Group

1812

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date
*1 ✓	4,761,371	02.08.88	Bell et al.			
*2 ✓	4,935,341	19.06.90	Bargmann et al.			
*3 ✓	4,968,603	06.11.90	Slamon et al.			
*4	5,030,576	09.07.91	Dull et al.			
*5	5,081,228	14.01.92	Dower et al.			
*6	5,126,433	30.06.92	Maddon et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes No
SW	7	WO 89/01973	09.03.89	PCT		

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*8	Akiyama et al., "The product of the human c-erbB-2 Gene: a 185-Kilodalton Glycoprotein with tyrosine Kinase Activity" <u>Science</u> 232:1644-1646 (1986)
*9	Bargmann et al., "The neu oncogene encodes an epidermal growth factor receptor-related protein" <u>Nature</u> 319:226-230 (1986)
*10	Bernards et al., "Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector" <u>Proc. Natl. Acad. Sci. USA</u> 84:6854-6858 (1987)
*11	Coussens et al., "Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene" <u>Science</u> 230:1132-1139 (1985)
*12	Drebin et al., "Down-modulation of an oncogene protein product in reversion of the transformed phenotype by monoclonal antibodies" <u>Cell</u> 41(3):697-706 (1985)
*13	Drebin et al., "Inhibition of Tumor Growth by a Monoclonal Antibody Reactive with an Oncogene-Encoded Tumor Antigen" <u>Proc. Natl. Acad. Sci. USA</u> 83:9129-9133 (1986)
*14	Drebin et al., "Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo" <u>Oncogene</u> 2:273-277 (1988)
*15	Drebin et al., "Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo" <u>Oncogene</u> 2(4):387-394 (1988)
*16	Graham et al., "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA" <u>Virology</u> 52:456-467 (1973)
*17	Hopp et al., "Prediction of protein antigenic determinants from amino acid sequences" <u>Proc. Natl. Acad. Sci. USA</u> 78(6):3824-3828 (1981)
*18	Hudziak et al., "Amplified Expression of the HER2/ERBB2 Oncogene Induces Resistance to Tumor Necrosis Factor α in NIH 3T3 Cells" <u>Proc. Natl. Acad. Sci. USA</u> 85:5102-5106 (1988)
*19	Hudziak et al., "Increased expression of the putative growth factor receptor p185 ^{HER2} causes transformation and tumorigenesis of NIH 3T3 cells" <u>Proc. Natl. Acad. Sci. USA</u> 84:7159-7163 (1987)


Examiner

STEPHEN WALSH

Date Considered

11-3-95

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P0554C2

Serial No.

08/355,460

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Hudziak, R. et al.

Filing Date

13 Dec 1994

Group

1812

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*20	Hudziak et al., "p185HER2 Monoclonal Antibody has Anti-Proliferative Effects in Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor" <u>Molecular & Cellular Biology</u> 9(3 Abs. 105430):1165-1172 (1989)
*21	Kane et al., "Formation of recombinant protein inclusion bodies in Escherichia coli" <u>Tibtech</u> 6:95-101 (1988)
*22	Kaufman et al., "Amplification and Expression of Sequences Cotransfected with a Modular Dihydrofolate Reductase Complementary DNA Gene" <u>J. Mol. Biol.</u> 159:601-621 (1982)
*23	King et al., "Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma" <u>Science</u> 229:974-976 (1985)
*24	Kraus et al., "Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms" <u>EMBO Journal</u> 6(3):605-610 (1987)
*25	Langton et al., "An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene" <u>Cancer Research</u> 51:2593-2598 (1991)
*26	Lin et al., "A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells" <u>Oncogene</u> 6:639-643 (1991)
*27	Margalit et al., "Prediction of Immunodominant Helper T Cell Antigenic Sites from the Primary Sequence" <u>J. Immunol.</u> 138(7):2213-2229 (1987)
*28	Masuko et al., "A murine monoclonal antibody that recognizes an extracellular domain of the human c-erbB-2 protooncogene product" <u>Jpn J. Cancer Res.</u> 80:10-14 (1989)
*29	Padhy et al., "Identification of a Phosphoprotein Specifically Induced by the Transforming DNA of Rat Neuroblastomas" <u>Cell</u> 28:865-871 (1982)
*30	Schecter et al., "The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen" <u>Nature</u> 312:513-516 (1984)
*31	Schein, Catherine H., "Production of soluble recombinant proteins in bacteria" <u>Bio/Technology</u> 7:1141-1149 (1989)
*32	Semba et al., "A v-erbB-related protooncogene c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma" <u>Proc. Natl. Acad. Sci. USA</u> 82:6497-6501 (1985)
*33	Shepard et al., "P185HER2 Monoclonal Antibody has Anti-Proliferative Effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor" <u>J. Cell Biochem.</u> (Abstract D253) pps. 42 (1989)
*34	Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene" <u>Science</u> 235:177-182 (1987)
*35	Van de Vijver et al., "Amplification of the neu (c-erbB-2) Oncogene in Human Mammary Tumors Is Relatively Frequent and Is Often Accompanied by Amplification of the Linked c-erbA Oncogene" <u>Molecular & Cellular Biology</u> 7(5):2019-2023 (1987)
*36	Weber et al., "Medium-scale ligand-affinity purification of two soluble forms of human interleukin-2 receptor" <u>J. Chromatography</u> 431:55-63 (1988)
*37	Yamamoto et al., "Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor" <u>Nature</u> 319:230-34 (1986)
*38	Yanisch-Perron et al., "Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors" <u>Gene</u> 33:103-119 (1985)
*39	Yarden et al., "Epidermal Growth Factor Induces Rapid, Reversible Aggregation of the Purified Epidermal Growth Factor Receptor" <u>Biochemistry</u> 26:1443-1451 (1987)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P0554C2Serial No.
08/355,460

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Hudziak, R. et al.

Filing Date

13 Dec 1994

Group

1812

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- | | |
|-----|---|
| *40 | Yarden et al., "Growth Factor Receptor Tyrosine Kinases" <u>Ann. Rev. Biochem.</u> 57:443-478 (1988) |
| *41 | Yarden et al., "Molecular Analysis of Signal Transduction by Growth Factors" <u>Biochemistry</u> 27(9):3113-3119 (1988) |
| *42 | Yokota et al., "Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue" <u>Oncogene</u> 2:283-287 (1988) |
| *43 | Zhou et al., "Association of Multiple Copies of the c-erbB-2 Oncogene with Spread of Breast Cancer" <u>Cancer Research</u> 47:6123-6125 (1987) |

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.